<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667690</url>
  </required_header>
  <id_info>
    <org_study_id>CD101.IV.3.05</org_study_id>
    <nct_id>NCT03667690</nct_id>
  </id_info>
  <brief_title>Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis</brief_title>
  <acronym>ReSTORE</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cidara Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cidara Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious
      and safe in the treatment of candidemia and/or invasive candidiasis when compared to
      caspofungin (followed by optional oral fluconazole).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3, multicenter, prospective, randomized, double-blind, efficacy and safety study of
      Rezafungin for Injection versus an active comparator regimen of caspofungin followed by
      optional oral fluconazole step-down therapy in subjects with candidemia and/or invasive
      candidiasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality (US FDA only)</measure>
    <time_frame>Day 30 (-2 days)</time_frame>
    <description>The number of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause mortality (US FDA only)</measure>
    <time_frame>Day 30 (-2 days)</time_frame>
    <description>The percentage of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Cure (EU only)</measure>
    <time_frame>Day 14 (±1 day)</time_frame>
    <description>The number of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the modified Intent to Treat (mITT2) population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Cure (EU only)</measure>
    <time_frame>Day 14 (±1 day)</time_frame>
    <description>The percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the modified Intent to Treat (mITT) population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Cure</measure>
    <time_frame>Day 14 (±1 day)</time_frame>
    <description>The number of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Cure</measure>
    <time_frame>Day 5, Day 30 (-2 days), EOT (≤2 days of last dose) and Follow-up (Days 52-59)</time_frame>
    <description>The number of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Cure</measure>
    <time_frame>Day 14 (±1 day)</time_frame>
    <description>The percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Cure</measure>
    <time_frame>Day 5, Day 30 (-2 days), EOT (≤2 days of last dose) and Follow-up (Days 52-59)</time_frame>
    <description>The percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality (EU only)</measure>
    <time_frame>Day 30 (-2 days)</time_frame>
    <description>The number of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality (EU only)</measure>
    <time_frame>Day 30 (-2 days)</time_frame>
    <description>The percentage of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Global Response (as confirmed by the DRC)</measure>
    <time_frame>Day 5, Day 30 (-2 days), End Of Treatment (≤2 days of last dose) and Follow-up (Days 52-59).</time_frame>
    <description>The number of subjects with a global response of cure, failure, or indeterminate will be presented by treatment group in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Global Response (as confirmed by the DRC)</measure>
    <time_frame>Day 5, Day 30 (-2 days), End Of Treatment (≤2 days of last dose) and Follow-up (Days 52-59).</time_frame>
    <description>The percentage of subjects with a global response of cure, failure, or indeterminate will be presented by treatment group in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Mycological Response</measure>
    <time_frame>Day 5, Day 14 (±1 day), Day 30 (-2 days), End Of Treatment (≤2 days of last dose), and Follow-up (Days 52-59).</time_frame>
    <description>The number of subjects with a mycological response of eradication, failure, or indeterminate, by treatment group, in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Mycological Response</measure>
    <time_frame>Day 5, Day 14 (±1 day), Day 30 (-2 days), End Of Treatment (≤2 days of last dose), and Follow-up (Days 52-59).</time_frame>
    <description>The percentage of subjects with a mycological response of eradication, failure, or indeterminate, by treatment group, in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Clinical Cure</measure>
    <time_frame>Day 5, Day 14 (±1 day), Day 30 (-2 days), End Of Treatment (≤2 days of last dose), and Follow-up (Days 52-59).</time_frame>
    <description>The number of subjects with a clinical response of cure, failure, or indeterminate, presented by treatment group, in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Clinical Cure</measure>
    <time_frame>Day 5, Day 14 (±1 day), Day 30 (-2 days), End Of Treatment (≤2 days of last dose), and Follow-up (Days 52-59).</time_frame>
    <description>The percentage of subjects with a clinical response of cure, failure, or indeterminate, presented by treatment group, in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events [Safety and Tolerability]</measure>
    <time_frame>Day 1 through Follow-up visit (Days 52-59)</time_frame>
    <description>Number of Subjects with Incidence of Treatment Emergent Adverse Events based on clinical chemistry, hematology and urine analysis laboratory test, vital sign, physical exams and ECG abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Pharmacokinetics (Cmax)</measure>
    <time_frame>Day 1; Days 2, 3, 4, or 5 (one sample on one day only); Day 8; Day 14 (for subjects not receiving a Day 15 dose); Day 15 (if applicable) and Day 22 (if applicable)</time_frame>
    <description>Evaluate maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Pharmacokinetics (Time to Cmax [Tmax])</measure>
    <time_frame>Day 1; Days 2, 3, 4, or 5 (one sample on one day only); Day 8; Day 14 (for subjects not receiving a Day 15 dose); Day 15 (if applicable) and Day 22 (if applicable)</time_frame>
    <description>Evaluate Tmax (time to Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Pharmacokinetics (AUC)</measure>
    <time_frame>Day 1; Days 2, 3, 4, or 5 (one sample on one day only); Day 8; Day 14 (for subjects not receiving a Day 15 dose); Day 15 (if applicable) and Day 22 (if applicable)</time_frame>
    <description>Evaluate area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Radiological Cure</measure>
    <time_frame>Day 5, Day 14 (±1 day), Day 30 (-2 days), EOT (≤2 days of last dose), and Follow-up (Days 52-59)</time_frame>
    <description>The number of invasive candidiasis subjects with radiological cure, failure, or indeterminate, presented by treatment group, in the mITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Radiological Cure</measure>
    <time_frame>Day 5, Day 14 (±1 day), Day 30 (-2 days), EOT (≤2 days of last dose), and Follow-up (Days 52-59)</time_frame>
    <description>The percentage of invasive candidiasis subjects with radiological cure, failure, or indeterminate, presented by treatment group, in the mITT population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Candidemia</condition>
  <condition>Mycoses</condition>
  <condition>Fungal Infection</condition>
  <condition>Invasive Candidiases</condition>
  <arm_group>
    <arm_group_label>Group 1: Rezafungin for Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.
Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Caspofungin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.
If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rezafungin for Injection</intervention_name>
    <description>Intravenous antifungal therapy</description>
    <arm_group_label>Group 1: Rezafungin for Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin</intervention_name>
    <description>Intravenous antifungal therapy</description>
    <arm_group_label>Group 2: Caspofungin</arm_group_label>
    <other_name>Cancidas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Oral antifungal therapy</description>
    <arm_group_label>Group 2: Caspofungin</arm_group_label>
    <other_name>generic fluconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Group 2: Caspofungin</arm_group_label>
    <other_name>placebo infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral placebo</intervention_name>
    <description>Microcrystalline cellulose</description>
    <arm_group_label>Group 1: Rezafungin for Injection</arm_group_label>
    <other_name>encapsulated cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to provide written informed consent. If the subject is unable to
             consent for himself/herself, a legally acceptable representative must provide informed
             consent on his/her behalf.

          2. Males or females ≥18 years of age.

          3. Established mycological diagnosis of candidemia and/or invasive candidiasis from a
             sample taken ≤4 days (96 hours) before randomization defined as

               -  ≥1 blood culture positive for yeast or Candida OR

               -  Positive test for Candida from a Sponsor-approved rapid IVD OR

               -  Positive gram stain (or other method of direct microscopy) for yeast or positive
                  culture for Candida spp. from a specimen obtained from a normally sterile site.

          4. Presence of one or more systemic signs attributable to candidemia or invasive
             candidiasis appearing from ≤12 hours prior to the qualifying positive culture through
             time of randomization.

          5. Willing to initiate or continue medical treatment to cure infections, including
             receipt of antibiotics and surgical procedures, if required.

          6. Female subjects of childbearing potential (all female subjects between 18 years &lt;2
             years post-menopausal unless surgically sterile) must agree to and comply with using
             one barrier method (e.g., female condom with spermicide) plus one other highly
             effective method of birth control, or sexual abstinence while participating in this
             study. Male subjects must be vasectomized, abstain from sexual intercourse, or agree
             to use barrier contraception, and also agree not to donate sperm while participating
             in the study and for 90 days thereafter (and at least 120 days from the last dose of
             study drug).

          7. For Candidemia only subjects, drawing of a set of blood cultures within 12 hours prior
             to randomization in the study. The result of these blood cultures is not required for
             inclusion in the study.

        Exclusion Criteria:

          1. Any of the following forms of invasive candidiasis at baseline:

               1. Septic arthritis in a prosthetic joint (septic arthritis in a native joint is
                  allowed)

               2. Osteomyelitis

               3. Endocarditis or myocarditis

               4. Meningitis, endophthalmitis, chorioretinitis, or any central nervous system
                  infection

               5. Chronic disseminated candidiasis

               6. Urinary tract candidiasis due to ascending Candida infection secondary to
                  obstruction or surgical instrumentation of the urinary tract

          2. Received systemic treatment with an antifungal agent at approved doses for treatment
             of candidemia for &gt;48 hours (e.g., &gt;2 doses of a once daily antifungal agent or &gt;4
             doses of a twice daily antifungal agent) ≤4 days (96 hours) before randomization

             a. Exception: Receipt of antifungal therapy to which any Candida spp. isolated in
             culture is not susceptible

          3. Alanine aminotransferase or aspartate aminotransferase levels &gt;10-fold the upper limit
             of normal

          4. Severe hepatic impairment in subjects with a history of chronic cirrhosis (Child-Pugh
             score &gt;9)

          5. Presence of an indwelling vascular catheter or device that cannot be removed or an
             abscess that cannot be drained and is likely to be the source of candidemia or
             invasive candidiasis

          6. Known hypersensitivity to Rezafungin for Injection, caspofungin, any echinocandin, or
             to any of their excipients

          7. Meets National Cancer Institute Common Terminology Criteria for Adverse Events,
             version 5, criteria for ataxia, tremor, motor neuropathy, or sensory neuropathy of
             Grade 2 or higher

          8. History of severe ataxia, tremor, or neuropathy or a diagnosis of multiple sclerosis
             or a movement disorder (including Parkinson's Disease or Huntington's Disease)

          9. Planned or ongoing therapy at Screening with a known neurotoxic medication

         10. Previous participation in this or any previous rezafungin study

         11. Current participation in another interventional treatment trial with an
             investigational agent

         12. Recent use of an investigational medicinal product within 28 days of the first dose of
             study drug or presence of an investigational device at the time of screening.

         13. Pregnant or lactating females

         14. The Principal Investigator (PI) is of the opinion the subject should not participate
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taylor Sandison, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Cidara Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Mena</last_name>
    <phone>858-888-7868</phone>
    <email>clinicaltrialinfo@cidara.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Arizona Division of Infectious Diseases</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen L Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mecury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ID Clinical Research, Ltd.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Falk Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reading Hospital and Medical Center</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Public Hospital</name>
      <address>
        <city>Northmead</city>
        <state>New South Wales</state>
        <zip>2152</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Womens Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital (RMH)</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brugmann University Hospital Center</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luc University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven, Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Puls</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment and Emergency Medicine N.I. Pirogov EAD, Sofia, Clinic of Purulent-Septic Surgery</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment and Emergency Medicine N.I. Pirogov EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy - Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris University Hospitals Center - Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;, 5th Department of Internal Medicine and Infectious Diseases Unit</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Laikon&quot;, Infectious Diseases Unit</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Laikon&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>35254</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>H̱olon</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Baruch Padeh Medical Center</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>1311001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinic S. Orsola-Malpighi, Dept. of Organ Impairment and Transplants</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Large Metropolitan Hospital Niguarda, Infectious Diseases Department</name>
      <address>
        <city>Milan</city>
        <zip>20161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Polyclinic Hospital of Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Modena</name>
      <address>
        <city>Modena</city>
        <zip>71-41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Polyclinic Hospital &quot;Paolo Giaccone&quot; Palermo, Infectious Disease Department, ICU</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Integrated University Health Authority of Trieste</name>
      <address>
        <city>Trieste</city>
        <zip>34125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Integrated University Hospital &quot;Santa Maria della Misericordia&quot; of Udine</name>
      <address>
        <city>Udine</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <state>Gangwon-do</state>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06793</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cruces</name>
      <address>
        <city>Baracaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar, Department of Infectious Diseases</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron (HUVH)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parc Tauli Health Corporation</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Clinical San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University and Polytechnic Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mena</last_name>
      <phone>858-888-7868</phone>
      <email>clinicaltrialinfo@cidara.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycoses</keyword>
  <keyword>Candidiasis</keyword>
  <keyword>Candidiasis, Invasive</keyword>
  <keyword>Candidemia</keyword>
  <keyword>Fungemia</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Invasive Fungal Infections</keyword>
  <keyword>Systemic Inflammatory Response Syndrome</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Caspofungin</keyword>
  <keyword>Echinocandins</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Anti-infective Agents</keyword>
  <keyword>14-alpha Demethylase Inhibitors</keyword>
  <keyword>Cytochrome P-450 Enzyme Inhibitors</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Steroid Synthesis Inhibitors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Cytochrome P-450 CYP2C9 Inhibitors</keyword>
  <keyword>Cytochrome P-450 CYP2C19 Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidemia</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Rezafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

